Anthralin

CHF 77.00
In stock
CDX-D0308-G0011 gCHF 77.00
CDX-D0308-G0055 gCHF 306.00
More Information
Product Details
Synonyms Dithranol; 1,8-Dihydroxyanthrone; Anthracene-1,8,9-triol; NSC 43970; NSC 629313
Product Type Chemical
Properties
Formula C14H10O3
MW 226.2
CAS 1143-38-0
RTECS CB8927000
Source/Host Chemicals Synthetic.
Purity Chemicals ≥98% (HPLC)
Appearance Faint yellow to yellow powder.
Solubility Soluble in acetone.
Identity Determined by NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key NUZWLKWWNNJHPT-UHFFFAOYSA-N
Smiles OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Anthralin is a leukotriene biosynthesis inhibitor. It inhibits LTB4 ω-oxidation and disrupts mitochondria function. Anthralin is used in the treatment of psoriasis, as a fungicide, in the treatment of ringworm infections and in chronic dermatoses. It accumulates in mitochondria where it interferes with the supply of energy to the cell, probably by the oxidation of dithranol releasing free radicals. This impedes DNA replication and so slows the excessive cell division that occurs in psoriatic plaques. Numerous studies have demonstrated anti-proliferative and anti-inflammatory effects of anthralin on psoriatic and normal skin. It is also used as matrix substance for MALDI-MS (matrix-assisted laser desorption ionization MS).

Product References

(1) R.E. Ashton, et al.; J. Am. Acad. Dermatol. 9, 173 (1983) | (2) J.M. Schröder; J. Invest. Dermatol. 87, 624 (1986) | (3) C.E. Orfanos, et al.; Drugs 34, 459 (1987) (Review) | (4) L. Kemeny, et al.; Skin Pharmacol. 3, 1 (1990) | (5) K. Müller; Biochem. Pharmacol. 53, 1215 (1997) (Review) | (6) K. Pavithran; Indian J. Dermatol. Venereol. Leprol. 67, 104 (2001) | (7) C.H. Le, et al.; Anal. Chem. 84, 8391 (2012) | (8) C. Ronpirin & T. Tencomnao; Genet. Mol. Res. 11, 412 (2012) | (9) S.E. George, et al.; J. Pharm. Pharmacol. 65, 552 (2013)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.